Benzinga
Benzinga
Benzinga
lunedì, settembre 28

SELLAS Life Sciences Group Inc

SLSNASDAQ
Trade with Public
Trade with Public
$11.59
-0.02-0.17%
In chiusura: Sep 28, 5:00 PM EST
$11.53
-0.06-0.52%
Post-mercato: 7:43 PM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaOpzioniRapporto azionario

SELLAS Life Sciences Gr Analyst Price Targets

Wall Street analyst price targets and consensus rating for SELLAS Life Sciences Gr (SLS).

Price Target Range — 3 Quarters

Analyst Consensus — 2 Analysts

2Buy
Consensus RatingOverweight# Analysts2Avg. Consensus PT$7Upside to Avg. PT-43.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →
DateFirmAnalystActionRating ChangePrice Target
Mar 12, 2026Maxim GroupJason McCarthyPT RaiseBuy$7→$10
Jul 16, 2025Maxim GroupJason McCarthyPT RaiseBuy$4→$7
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Maxim Group Maintains Buy on SELLAS Life Sciences Gr, Raises Price Target to $7

Maxim Group analyst Jason McCarthy maintains SELLAS Life Sciences Gr (NASDAQ:SLS) with a Buy and raises the price target from $4 to $7.
Benzinga Newsdesk

Galena Biopharma Upgraded to Buy: Here's What You Should Know

Investors might want to bet on Galena Biopharma, Inc. (NASDAQ: SLS), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.
Zacks

PRO
Cantor Fitzgerald Reiterates Overweight on SELLAS Life Sciences Gr, Maintains $3 Price Target

Cantor Fitzgerald analyst Li Watsek reiterates SELLAS Life Sciences Gr (NASDAQ:SLS) with a Overweight and maintains $3 price target.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on SELLAS Life Sciences Gr, Maintains $3 Price Target

Cantor Fitzgerald analyst Li Watsek reiterates SELLAS Life Sciences Gr (NASDAQ:SLS) with a Overweight and maintains $3 price target.
Benzinga Newsdesk

PRO
Alliance Global Partners Maintains Buy on SELLAS Life Sciences Gr, Lowers Price Target to $8

Alliance Global Partners analyst James Molloy maintains SELLAS Life Sciences Gr (NASDAQ:SLS) with a Buy and lowers the price target from $14 to $8.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on SELLAS Life Sciences Gr, Lowers Price Target to $6

Cantor Fitzgerald analyst Li Watsek maintains SELLAS Life Sciences Gr (NASDAQ:SLS) with a Overweight and lowers the price target from $10 to $6.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved